Convulex^®

Convulex^® contains the active substance sodium valproate.

Convulex^® is a medicinal product for the treatment of seizure disorders (antiepileptic drug). 

Enteric-coated capsules, oral solution:

Epilepsies: for the treatment of primary generalised, secondary generalised and partial epileptic seizure forms.

Bipolar disorders: for the treatment of manic episodes in bipolar disorder when lithium is contraindicated or not tolerated. Continued treatment after a manic episode may be considered in those patients who have responded to valproate therapy for acute mania.

Migraine: for prophylaxis of migraine attacks when other medicines for migraine are not sufficiently effective.

Prolonged-release tablets:

Epilepsies: for the treatment of primary generalised, secondary generalised and partial epileptic seizure forms.

Bipolar disorders: for the treatment of manic episodes in bipolar disorder when lithium is contraindicated or not tolerated. Continuing treatment after a manic episode may be considered in patients who have responded to valproate in the treatment of acute mania.

Syrup:

Epilepsies: Convulex^® 50 mg/ml syrup for children is used for the treatment of primary generalised, secondary generalised and partial epileptic seizure forms.

Solution for injection:

For the treatment of epileptic seizures and manic episodes in bipolar disorder when oral administration of sodium valproate is not suitable or temporarily not possible.

Also effective for:

• generalised seizures in the form of absences, myoclonic seizures, tonic-clonic seizures, atonic seizures and mixed seizure types,
  Focal seizures in the form of simple or complex seizures, secondary generalised seizures and specific syndromes (West syndrome, Lennox-Gastaut syndrome).
• Treatment of manic episodes in bipolar disorder when lithium is contraindicated or not tolerated. Continued treatment after a manic episode may be considered in those patients who have responded to valproate therapy for acute mania.

In young children, sodium valproate is the drug of first choice only in exceptional cases; Convulex^® solution for injection should be used only with special caution after a strict risk-benefit assessment and, if possible, as monotherapy.

Officially instructed educational material Valproate